Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | NAMPT | P43490 | 1/20 | 0.43 |
| ▸ | BRD4 | O60885 | 3/20 | 0.43 |
| ▸ | GLS | O94925 | 2/20 | 0.43 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.43 |
| ▸ | CTSL | P07711 | 1/20 | 0.43 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.42 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.42 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.42 |
| ▸ | ATM | Q13315 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5969172 | 0.80 | KMT2A (0.45) | MEN1KMT2AOPRD1HDAC1ATM | |
| SCHEMBL12318659 | 0.79 | GLS (0.49) | NAMPTBRD4GLSCREBBPHDAC1 | |
| SCHEMBL21089822 | 0.78 | GLS (0.48) | NAMPTBRD4GLSCREBBPHDAC1 | |
| SCHEMBL28637112 | 0.78 | GLS (0.48) | NAMPTBRD4GLSCREBBPHDAC1 | |
| SCHEMBL23413688 | 0.77 | GLS (0.46) | BRD4GLSCREBBPHDAC1ATM | |
| SCHEMBL14898071 | 0.77 | GLS (0.48) | NAMPTBRD4GLSCREBBPHDAC1 | |
| SCHEMBL27779357 | 0.77 | GLS (0.47) | NAMPTBRD4GLSCREBBPHDAC1 | |
| SCHEMBL31351013 | 0.76 | MAOB (0.48) | MEN1KMT2ANPSR1LMNA | |
| SCHEMBL31389110 | 0.76 | SYK (0.46) | NAMPTBRD4GLSCREBBPHDAC1 | |
| SCHEMBL3838871 | 0.75 | CA12 (0.63) | MEN1KMT2ALMNANAMPTHDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6984627-B1 | Peptide derivatives | ASTRAZENECA AB (SE) | 2006-01-10 | — | — | US | disclosed |
| US-20050222395-A1 | New peptide derivatives | ASTRAZENECA AB (SE) | 2005-10-06 | — | — | US | disclosed |
| EP-0701568-B1 | NEW PEPTIDE DERIVATIVES | ASTRAZENECA AB (SE) | 2001-04-25 | — | — | EP | disclosed |
| EP-1067136-A1 | New peptide derivatives | AstraZeneca AB (SE) | 2001-01-10 | — | — | EP | disclosed |
| US-5939392-A | THROMBIN INHIBITORS, ANTICOAGULANTS AND ANTIINFLAMMATORY AGENTS | ASTRA AKTIEBOLAG (SE) | 1999-08-17 | — | — | US | disclosed |
| US-5856307-A | Peptide derivatives as kininogenase inhibitors | ASTRA AKTIEBOLAG (SE) | 1999-01-05 | — | — | US | disclosed |
| US-5783563-A | Method for treatment or prophylaxis of venous thrombosis | ASTRA AKTIEBOLAG | 1998-07-21 | — | — | US | disclosed |
| US-5780631-A | ANTICOAGLUANT | ASTRA AKTIEBOLAG (SE) | 1998-07-14 | — | — | US | disclosed |
| US-5723444-A | ENZYME INHIBITORS AND ANTICOAGULANTS | ASTRA AB (SE) | 1998-03-03 | — | — | US | disclosed |
| US-5602253-A | STARTING MATERIAL FOR SERINE PROTEASE INHIBITORS | AKTIEBOLAGET ASTRA (SE) | 1997-02-11 | — | — | US | disclosed |
| EP-0701568-A1 | NEW PEPTIDE DERIVATIVES | Astra Aktiebolag (SE) | 1996-03-20 | — | — | EP | disclosed |
| WO-1994029336-A1 | NEW PEPTIDE DERIVATIVES | ASTRA AKTIEBOLAG (SE) | 1994-12-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050222395-A1 | New peptide derivatives | SERPINE1, SERPINC1, SPINT2 | MEN1 1137/4885KMT2A 4410/4885NPSR1 551/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.